AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Disorders: Lorglumide sodium salt has been investigated for its therapeutic potential in various gastrointestinal disorders, including functional dyspepsia, irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD). As a cholecystokinin receptor antagonist, lorglumide may modulate gastrointestinal motility, reduce visceral hypersensitivity, and decrease gastric acid secretion, which could alleviate symptoms such as abdominal pain, bloating, and reflux.
Pain Management: Cholecystokinin receptors are involved in pain processing, and lorglumide sodium salt has been explored for its analgesic properties. It may exert antinociceptive effects by inhibiting the release of neurotransmitters involved in pain signaling pathways. Research suggests that lorglumide may have potential as an adjuvant therapy for chronic pain conditions, although further studies are needed to elucidate its efficacy and safety profile.
Appetite Regulation and Weight Management: Cholecystokinin plays a role in appetite regulation and satiety signaling. By blocking cholecystokinin receptors, lorglumide sodium salt may modulate appetite and food intake. It has been studied as a potential adjunctive treatment for obesity and eating disorders, although clinical data on its efficacy in this context are limited.
Pancreatitis: Cholecystokinin receptors are also present in the pancreas, where they regulate pancreatic enzyme secretion. Lorglumide sodium salt has been investigated for its potential therapeutic role in acute pancreatitis and chronic pancreatitis by modulating pancreatic exocrine function. However, more research is needed to determine its effectiveness and safety in the management of pancreatic disorders.
Psychiatric Disorders: Cholecystokinin receptors are expressed in the central nervous system, where they modulate neurotransmitter release and synaptic transmission. Lorglumide sodium salt has been studied for its effects on mood, anxiety, and stress-related disorders. Preclinical studies suggest that it may have anxiolytic and antidepressant-like effects, but further clinical trials are necessary to evaluate its efficacy and potential utility in psychiatric practice.
Cancer Therapy: Cholecystokinin receptors are overexpressed in certain types of cancer cells, including pancreatic cancer and neuroendocrine tumors. Lorglumide sodium salt has been investigated as a potential adjuvant therapy for cancer treatment by targeting cholecystokinin receptor-mediated signaling pathways. It may enhance the efficacy of conventional chemotherapy and radiotherapy regimens, although clinical data are limited, and more research is needed to assess its therapeutic potential in oncology.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4 | 0.1 | 39 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.2 | 2 |
| Allergic Rhinitis (Hay Fever) | 1.6 | 1.7 | -0.06 |
| Allergies | 4.3 | 2.4 | 0.79 |
| Allergy to milk products | 1.1 | 0.6 | 0.83 |
| Alopecia (Hair Loss) | 1.9 | 1.9 | |
| Alzheimer's disease | 2.6 | 5.4 | -1.08 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.6 | 2.83 |
| Ankylosing spondylitis | 3.7 | 1.5 | 1.47 |
| Anorexia Nervosa | 0.2 | 2.2 | -10 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.1 | 14 |
| Asthma | 0.8 | 0.9 | -0.13 |
| Atherosclerosis | 0.8 | 1.5 | -0.88 |
| Atrial fibrillation | 3.3 | 1.6 | 1.06 |
| Autism | 7 | 7.5 | -0.07 |
| Barrett esophagus cancer | 0.4 | 0.4 | 0 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 1.1 | 1.1 | 0 |
| Brain Trauma | 0.6 | 0.6 | 0 |
| Carcinoma | 3.2 | 2.5 | 0.28 |
| Celiac Disease | 1.6 | 3.7 | -1.31 |
| Cerebral Palsy | 1.6 | 1.4 | 0.14 |
| Chronic Fatigue Syndrome | 4.3 | 4.9 | -0.14 |
| Chronic Kidney Disease | 1.4 | 1.4 | 0 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 0.5 | 3.4 |
| Chronic Urticaria (Hives) | 1.3 | 1.3 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.8 | 1.4 | -0.75 |
| Colorectal Cancer | 3.3 | 0.9 | 2.67 |
| Constipation | 0.7 | 0.7 | 0 |
| Coronary artery disease | 1.5 | 0.9 | 0.67 |
| COVID-19 | 9.8 | 12.7 | -0.3 |
| Crohn's Disease | 5.4 | 4.7 | 0.15 |
| cystic fibrosis | 0.2 | 0.9 | -3.5 |
| deep vein thrombosis | 0.2 | 0.9 | -3.5 |
| Depression | 7.9 | 5.7 | 0.39 |
| Dermatomyositis | 0.4 | 0.3 | 0.33 |
| Eczema | 1.2 | 2.3 | -0.92 |
| Endometriosis | 2.2 | 1.2 | 0.83 |
| Eosinophilic Esophagitis | 0.4 | -0.4 | |
| Epilepsy | 2.4 | 1.7 | 0.41 |
| Fibromyalgia | 2.5 | 1.6 | 0.56 |
| Functional constipation / chronic idiopathic constipation | 4 | 2.9 | 0.38 |
| gallstone disease (gsd) | 2.1 | 0.6 | 2.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 1.3 | -0.3 |
| Generalized anxiety disorder | 1.3 | 1.6 | -0.23 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 0.4 | -0.4 | |
| Graves' disease | 1.1 | 1.3 | -0.18 |
| Halitosis | 0.8 | 0.4 | 1 |
| Hashimoto's thyroiditis | 1.8 | 0.8 | 1.25 |
| Hidradenitis Suppurativa | 0.5 | 0.4 | 0.25 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.6 | 1.1 | 1.36 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.2 | 2.5 |
| hyperglycemia | 0.1 | 1.7 | -16 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.2 | 2.5 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 1.9 | 4.8 | -1.53 |
| Hypothyroidism | 0.9 | -0.9 | |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 4 | -4 | |
| Inflammatory Bowel Disease | 4.4 | 7.1 | -0.61 |
| Insomnia | 1.2 | 0.8 | 0.5 |
| Intelligence | 0.4 | 0.5 | -0.25 |
| Intracranial aneurysms | 1.3 | 0.2 | 5.5 |
| Irritable Bowel Syndrome | 3.9 | 3 | 0.3 |
| Liver Cirrhosis | 4 | 2.9 | 0.38 |
| Long COVID | 6.8 | 8 | -0.18 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.7 | 1.3 | -0.86 |
| ME/CFS with IBS | 0.9 | 2.3 | -1.56 |
| ME/CFS without IBS | 1.7 | 2.5 | -0.47 |
| Menopause | 2.2 | 2.2 | |
| Metabolic Syndrome | 6.3 | 6.8 | -0.08 |
| Mood Disorders | 10.3 | 5.8 | 0.78 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.5 | 2.4 |
| Multiple Sclerosis | 4.6 | 5.5 | -0.2 |
| Multiple system atrophy (MSA) | 1.9 | 1.1 | 0.73 |
| Neuropathy (all types) | 0.9 | 0.1 | 8 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 5.1 | -1.22 |
| NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
| Obesity | 7.4 | 3.6 | 1.06 |
| obsessive-compulsive disorder | 5.7 | 3.5 | 0.63 |
| Osteoarthritis | 2.7 | 0.3 | 8 |
| Osteoporosis | 1.6 | 1 | 0.6 |
| pancreatic cancer | 0.7 | 0.7 | |
| Parkinson's Disease | 1.8 | 3.1 | -0.72 |
| Polycystic ovary syndrome | 1.7 | 1.9 | -0.12 |
| Postural orthostatic tachycardia syndrome | 0.3 | 0.3 | 0 |
| Premenstrual dysphoric disorder | 1 | 0.2 | 4 |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Psoriasis | 4.1 | 2.4 | 0.71 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5 | 3.1 | 0.61 |
| Rosacea | 0.6 | 0.6 | 0 |
| Schizophrenia | 5.7 | 1.7 | 2.35 |
| scoliosis | 0.8 | -0.8 | |
| Sjögren syndrome | 3.2 | 2.9 | 0.1 |
| Sleep Apnea | 1.1 | 1.2 | -0.09 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | 0 |
| Stress / posttraumatic stress disorder | 2.1 | 1.6 | 0.31 |
| Systemic Lupus Erythematosus | 3.6 | 1.9 | 0.89 |
| Tic Disorder | 0.6 | 1.4 | -1.33 |
| Tourette syndrome | 0.1 | 0.4 | -3 |
| Type 1 Diabetes | 3.1 | 2 | 0.55 |
| Type 2 Diabetes | 6 | 5.1 | 0.18 |
| Ulcerative colitis | 2.4 | 3.7 | -0.54 |
| Unhealthy Ageing | 3.8 | 1.7 | 1.24 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.